Key Points
- CFO Matt Zuga sold 6,888 shares on Jan. 8 at an average price of $1.82 for $12,536.16, trimming his stake by 3.18% to 209,951 shares (about $382,110.82); the sale was disclosed in an SEC Form 4 filing.
- The CFO's sale was part of a cluster of insider sales from Jan. 5–12 (CEO ~26,472 shares, COO 3,530 shares, CFO 6,888 shares), totaling roughly ~37,000 shares for about ~$66,000, which the article says likely contributed to downward pressure on the stock.
- Analysts still hold a consensus "Moderate Buy" on ABOS with a $6.75 price target; the company has a market cap of about $104.2M and a 52‑week trading range of $0.86–$2.46.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 6,888 shares of the stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $1.82, for a total transaction of $12,536.16. Following the transaction, the chief financial officer owned 209,951 shares in the company, valued at approximately $382,110.82. The trade was a 3.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Matt Zuga also recently made the following trade(s):
- On Wednesday, January 7th, Matt Zuga sold 5,805 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.99, for a total transaction of $11,551.95.
- On Tuesday, January 6th, Matt Zuga sold 5,100 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.97, for a total transaction of $10,047.00.
- On Monday, January 5th, Matt Zuga sold 4,000 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.96, for a total transaction of $7,840.00.
Acumen Pharmaceuticals Stock Performance
Shares of ABOS stock opened at $1.72 on Tuesday. The firm has a market cap of $104.18 million, a price-to-earnings ratio of -0.77 and a beta of 0.23. Acumen Pharmaceuticals, Inc. has a 52-week low of $0.86 and a 52-week high of $2.46. The company has a quick ratio of 6.02, a current ratio of 6.02 and a debt-to-equity ratio of 0.29. The company's 50 day moving average is $1.93 and its 200 day moving average is $1.69.
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.19. On average, sell-side analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.
Institutional Trading of Acumen Pharmaceuticals
A number of institutional investors have recently bought and sold shares of ABOS. Hudson Bay Capital Management LP increased its stake in Acumen Pharmaceuticals by 7.1% during the 2nd quarter. Hudson Bay Capital Management LP now owns 825,004 shares of the company's stock valued at $957,000 after purchasing an additional 55,004 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Acumen Pharmaceuticals during the third quarter valued at $691,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Acumen Pharmaceuticals in the 2nd quarter valued at $291,000. Susquehanna International Group LLP raised its stake in Acumen Pharmaceuticals by 26.5% in the 3rd quarter. Susquehanna International Group LLP now owns 214,440 shares of the company's stock worth $367,000 after acquiring an additional 44,902 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in Acumen Pharmaceuticals by 45.4% in the 3rd quarter. Bank of America Corp DE now owns 213,729 shares of the company's stock worth $365,000 after acquiring an additional 66,720 shares during the last quarter. 71.01% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Acumen Pharmaceuticals
Here are the key news stories impacting Acumen Pharmaceuticals this week:
- Positive Sentiment: Analysts: ABOS carries a consensus "Moderate Buy" from analysts, which is supportive for the stock and may limit downside if clinical or corporate news is constructive. Article Title
- Neutral Sentiment: Short-interest report shows effectively zero short interest as of Jan. 12, but the published entry contains inconsistent/NaN figures — the data appears unreliable and likely doesn't explain today's move. Monitor future short-interest updates for clarity.
- Negative Sentiment: Insider selling: Several senior executives sold shares between Jan. 8–12. CEO Daniel O'Connell sold a total of 26,472 shares across three trades (avg. prices ~$1.73–$1.82), COO Russell Barton sold 3,530 shares (avg. $1.86) and CFO Matt Zuga sold 6,888 shares (avg. $1.82). Combined, executives sold roughly ~37k shares for roughly ~$66k in proceeds. While insiders still hold large positions (CEO still owns ~593k shares valued at ~ $1.0M), the cluster of recent sales can be perceived negatively by the market and likely contributed to downward pressure. Filing: SEC Form 4
Wall Street Analyst Weigh In
A number of equities analysts have commented on the stock. Bank of America reduced their target price on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, November 18th. Wall Street Zen upgraded shares of Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday, December 21st. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Acumen Pharmaceuticals in a report on Friday. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $6.75.
Check Out Our Latest Research Report on ABOS
Acumen Pharmaceuticals Company Profile
(
Get Free Report)
Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.
The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
